Navigation Links
"From Survive to Thrive" campaign seeks to enhance access to lifesaving donor milk in Neonatal Intensive Care Units in 2014
Date:11/22/2013

PHILADELPHIA, Nov. 22, 2013 /PRNewswire-iReach/ -- A forthcoming campaign to enhance access to human milk for premature infants in hospital settings was announced today by Elena Medo, Chair and CEO of Medolac Laboratories during a plenary presentation at the Annual International Meeting of the Academy of Breastfeeding Medicine.  

The Campaign sets an ambitious target to improve access to human milk in Neonatal Intensive Care Units from less than 5% today to 20% by the end of 2014.  "Nothing holds a greater opportunity to improve health outcomes for premature infants than the accessibility of safe, affordable and reliable supply of human milk adapted for their use".

The shortage of human milk in Neonatal Intensive Care Units has been well documented, including in an article published by Ms. Medo in the Journal of Breastfeeding Medicine (Vol. 8, No.5) earlier this month, highlighting the critical shortage of donor milk for very low birth weight (VLBW) infants despite the clear health advantages it brings, particularly by greatly reducing the incidence of gastrointestinal diseases such as sepsis and necrotizing enterocolitis. 

Achievement of this ambitious target will be met by greatly increasing the supply of donor milk through the development of cooperative milk banking.  Elena Medo has been a pioneer of the innovative coop model as a way to give donors a voice, fair compensation for their milk and provide incentive to donors to improve supply. 

Donor milk safety is also a key component of increasing access, since premature infants are often immunocompromised and experience a high risk of infection.  Medolac Laboratories requires blood screening of donor candidates, testing of each donor's milk for disease, contamination and drugs of abuse, testing of pooled donor milk for safety and nutrition as well as the testing of finished product. 
More information about the "From Survive to Thrive" campaign will be made available as Medolac makes progress towards fulfilling its objective in 2014.   

About Medolac:

Our vision is to provide human milk based therapies to critically ill babies and children on a global basis by applying proprietary biopharmaceutical processing methods that preserve the immune components in human milk while providing the safest, highest quality human milk formulations available to babies in need.    Medolac Laboratories is a Delaware registered, public benefit corporation (Neolac Inc. dba Medolac) headquartered at Lake Oswego, Oregon in the Pacific Northwest of the United States. 

Media Contact: Yvonne Arroyo, Medolac Laboratories, 8665997740, Media@medolac.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Medolac Laboratories
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. What Hospitals Must Do to Thrive -- Not Just Survive -- on Medicare Margins
2. Medtech companies urged to evolve business model to survive
3. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
4. UV Flu Technologies to Commence a National TV Advertising Campaign
5. Research Triangle Region Debuts Talent Attraction Campaign at BIO 2012
6. Mandy Moore Campaigns for Clean Water, GreenBeanBuddy Encourages Mothers to Help Through the Use of Green Cleaning Products
7. New "GMO Inside" Campaign Denounces Corporate Disinformation Campaign That Defeated Californias Prop 37
8. Adult Stem Cell Therapy Breakthrough Leads to Crowd Funding Campaign on Indiegogo.com for Centagen, Inc.
9. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
10. Texas Fertility Center ‘March Dadness’ Campaign Focuses on the Odds of Beating Male Infertility
11. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... BARBARA, CALIFORNIA (PRWEB) , ... October 10, 2017 ... ... management, technological innovation and business process optimization firm for the life sciences and ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation ...
Breaking Biology Technology:
(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
Breaking Biology News(10 mins):